RecruitingAlzheimer Disease
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Eligible age
55–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Sponsor: Baylor College of Medicine
You may qualify if…
- ✓ Age 55-85 years;
- ✓ Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
- ✓ Amyloid positivity on PET scan;
- ✓ Availability of a study partner.
You may not qualify if…
- ✕ hospitalization in past 3 months;
- ✕ use of insulin medications;
- ✕ untreated thyroid disease;
- ✕ creatinine levels \>1.5 mg/dL;
- ✕ hemoglobin concentration \<11.0 g/dL;
- ✕ known liver disease, or AST/ALT level \>2x ULN;
- ✕ history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
- ✕ untreated depression or other severe psychiatric disorders;
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT04740580 · last updated 2025-06-10